Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Nancy who wrote (4269)	7/12/1998 7:32:00 PM
From: Ibexx	Read Replies (2) \| Respond to of 9523

Thanks in advance for NEVER, ever posting to me again. To engage in a dialogue with folks who talk out of both sides of their mouths is not my favorite pasttime. No need to reply. Ibexx PS: go back and count how many times there has been....don't you ever get a hint?

To: Nancy who wrote (4269)	7/12/1998 7:44:00 PM
From: Judy	Read Replies (2) \| Respond to of 9523

We should know whether Enbrel phase III filing will be approved or not by October. Enbrel is a drug that when combined with current treatments for RA (such as gold treatments) will minimize their deteriorating effects. Current RA patients can only go so long on the existing treatments before their organs go into atrophy and then must switch to another drug protocol. Enbrel, the moment it is approved and goes commercial, will improve the quality of life for millions of RA patients. Within this context I am willing to invest in IMNX, trusting that it has prepared well for the phase III filing just it has well prepared for the previous filings. I say this in the context of a someone who has a relative with advanced RA. But FWIW the tape will not lie to me. As for PFE, I have no knowledge about Celebra nor its FDA filing schedule.